Author

B. Hann

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3 Biochemistry· 1 Bioengineering· 1 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 5 Research Focus:drug response / drug discovery· 4 Organism:human· 4 Assay:proteomics· 3 Assay:bulk RNA-seq· 2 Approach:statistical model· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1

Frequent Co-Authors

V. Steri· 5 shared D. Wang· 3 shared J. A. Wells· 2 shared Y.-H. T. Lin· 2 shared A. A. Kossiakoff· 1 shared A. H. Christian· 1 shared A. J. Martinko· 1 shared A. Kang· 1 shared

Activity by Year

2019-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

5 shared papersCancer Biology

V. Steri

Mutual co-authors in cluster

Author profile →

6 papers

Recent·Most cited

A reversible SRC-relayed COX2-inflammatory program drives therapeutic resistance in BRAF(V600E) colorectal tumors

A. Ruiz-Saenz, C. E. Atreya, C. Wang, B. Pan, C. A. Dreyer, D. Brunen, A. Prahallad, D. P. Munoz, D. J. Ramms, V. Burghi, D. S. Spassov, E. Fewings, Y. C. Hwang, C. Cowdrey, C. Moelders, , J.-P. Coppe

This study identifies a SRC-relayed COX2-inflammatory program that drives resistance to BRAF/MEK/EGFR therapies in BRAFV600E colorectal tumors and shows that co-targeting COX2 improves therapeutic outcomes.

bioRxiv · Oct 20, 2022 · PreprintCancer Biology

Functional multi-omics reveals genetic and pharmacologic regulation of surface CD38 in multiple myeloma

P. Choudhry, C. Kasap, B. Patino Escobar, O. Gugliemini, H. Geng, V. Sarin, A. Kang, A. Kishishita, S. Rampersaud, L. Sarah, Y.-H. T. Lin, N. Paranjape, P. Ramkumar, M. Marcoulis, D. Wang, , A. Wiita

This study uses multi-omics approaches to identify regulators of CD38 surface expression in multiple myeloma and assess the impact of therapies on CD38 levels and signaling.

bioRxiv · Aug 4, 2021 · PreprintCancer Biology

Targeting a proteolytic neo-epitope of CUB-domain containing protein 1 in RAS-driven cancer

S. A. Lim, J. Zhou, A. J. Martinko, Y.-H. Wang, E. V. Filippova, V. Steri, D. Wang, S. G. Remesh, J. Liu, B. Hann, A. A. Kossiakoff, M. J. Evans, K. K. Leung, J. A. Wells

The paper develops antibodies targeting proteolytic neo-epitopes of CDCP1 in RAS-driven cancers, showing improved tumor specificity and safety.

bioRxiv · Jun 14, 2021 · PreprintBiochemistry

Allosteric HSP70 inhibitors perturb mitochondrial proteostasis and overcome proteasome inhibitor resistance in multiple myeloma

I. D. Ferguson, Y.-H. T. Lin, C. Lam, H. Shao, M. Hale, K. M. Tharp, M. C. Mariano, V. Steri, D. Wang, P. Phojanokong, S. T. Tuomivaara, B. Hann, C. Driessen, B. V. Ness, J. E. Gestwicki, A. P. Wiita

This study identifies allosteric HSP70 inhibitors that overcome proteasome inhibitor resistance in multiple myeloma by targeting mitochondrial HSPA9 and disrupting mitoribosome stability.

bioRxiv · Apr 21, 2020Cancer Biology

Transit-amplifying cells coordinate changes in intestinal epithelial cell-type composition

L. E. Sanman, I. W. Chen, J. M. Bieber, V. Steri, B. Hann, L. F. Wu, S. J. Altschuler

The paper identifies that modulating transit-amplifying cell proliferation alters intestinal epithelial cell-type composition through lineage-based mechanisms.

bioRxiv · Mar 12, 2020Cell Biology

Systematic identification of engineered methionines and oxaziridines for efficient, stable, and site-specific antibody bioconjugation

S. K. Elledge, H. L. Tran, A. H. Christian, V. Steri, B. Hann, F. D. Toste, C. J. Chang, J. A. Wells

This study systematically identifies engineered methionines and oxaziridines for efficient, stable, and site-specific antibody bioconjugation, finding stable sulfimide modifications comparable to cysteine-maleimide conjugation.

bioRxiv · Aug 28, 2019Bioengineering